AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studySystematic reviewPeer review unconfirmed
Human MSCs' Effects on Immune Cells in Autoimmune Diseases
Research indicates that mesenchymal stem cells (MSCs) may regulate immune cell populations and reduce inflammation in autoimmune diseases like multiple sclerosis (MS). Specifically, MSCs can downregulate pro-inflammatory responses and promote regulatory immune cell types.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
This suggests MSCs might have therapeutic potential in managing autoimmune diseases, offering a possible pathway for future treatments.
What this does not prove
However, current evidence primarily comes from small, preliminary studies with limited follow-up and does not guarantee efficacy or long-term safety.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-28
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceImmunomodulatory Properties of Mesenchymal Stem Cells and Their Extracellular Vesicles: Potential Clinical Applications in Autoimmune Diseases. ↗DOI: 10.7759/cureus.117095
Supporting passages (7)
study designThis narrative review provides a narrative synthesis of MSC- and MSC-EV-mediated immunomodulation and its translational potential across four major autoimmune diseases: multiple sclerosis (MS), type 1 diabetes mellitus (T1D), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).
subjectsMechanistically, MSCs regulate both innate and adaptive immune cell populations, modulate pro- and anti-inflammatory cytokine secretion, downregulate pro-inflammatory Th1/Th17 responses, and promote regulatory phenotypes, including regulatory T cells, regulatory B cells, and M2-polarized macrophages.
findingsMechanistically, MSCs regulate both innate and adaptive immune cell populations, modulate pro- and anti-inflammatory cytokine secretion, downregulate pro-inflammatory Th1/Th17 responses, and promote regulatory phenotypes, including regulatory T cells, regulatory B cells, and M2-polarized macrophages.
limitationsPreclinical and clinical investigations suggest therapeutic potential across these diseases; however, much of the clinical evidence derives from small, early-phase, and frequently uncontrolled studies with limited follow-up, and safety outcomes vary according to MSC source, manufacturing process, dose, route of administration, and clinical indication.
limitationsthe absence of serious adverse events does not constitute definitive evidence of long-term safety.
limitationsthese findings should be regarded as preliminary evidence of therapeutic potential rather than established efficacy across autoimmune diseases.
publication datePublication date: 2026-09-28
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.